295 related articles for article (PubMed ID: 20932925)
41. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation.
Antin JH; Kim HT; Cutler C; Ho VT; Lee SJ; Miklos DB; Hochberg EP; Wu CJ; Alyea EP; Soiffer RJ
Blood; 2003 Sep; 102(5):1601-5. PubMed ID: 12730113
[TBL] [Abstract][Full Text] [Related]
42. Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Omer AK; Weisdorf DJ; Lazaryan A; Shanley R; Blazar BR; MacMillan ML; Brunstein C; Bejanyan N; Arora M
Biol Blood Marrow Transplant; 2016 May; 22(5):879-83. PubMed ID: 26743342
[TBL] [Abstract][Full Text] [Related]
43. New developments in the prophylaxis and treatment of graft versus host disease.
Simpson D
Expert Opin Pharmacother; 2001 Jul; 2(7):1109-17. PubMed ID: 11583062
[TBL] [Abstract][Full Text] [Related]
44. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin.
McCaul KG; Nevill TJ; Barnett MJ; Toze CL; Currie CJ; Sutherland HJ; Conneally EA; Shepherd JD; Nantel SH; Hogge DE; Klingemann HG
J Hematother Stem Cell Res; 2000 Jun; 9(3):367-74. PubMed ID: 10894358
[TBL] [Abstract][Full Text] [Related]
45. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.
Cutler C; Stevenson K; Kim HT; Richardson P; Ho VT; Linden E; Revta C; Ebert R; Warren D; Choi S; Koreth J; Armand P; Alyea E; Carter S; Horowitz M; Antin JH; Soiffer R
Blood; 2008 Dec; 112(12):4425-31. PubMed ID: 18776081
[TBL] [Abstract][Full Text] [Related]
46. Extracorporeal photopheresis for graft-versus-host disease: the role of patient, transplant, and classification criteria and hematologic values on outcome-results from a large single-center study.
Berger M; Albiani R; Sini B; Fagioli F
Transfusion; 2015 Apr; 55(4):736-47. PubMed ID: 25355659
[TBL] [Abstract][Full Text] [Related]
47. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus.
Przepiorka D; Ippoliti C; Khouri I; Anderlini P; Mehra R; Giralt S; Gajewski J; Fritsche H; Deisseroth AB; Cleary K; Champlin R; van Besien K; Andersson B; Korbling M
Transplantation; 1996 Dec; 62(12):1806-10. PubMed ID: 8990368
[TBL] [Abstract][Full Text] [Related]
48. The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation.
Markus PM; Cai X; Selvaggi G; Cooper M; Harnaha J; Fung JJ; Starzl TE
Transplant Proc; 1991 Dec; 23(6):3232-3. PubMed ID: 1721418
[No Abstract] [Full Text] [Related]
49. Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions.
Taylor PA; Lees CJ; Wilson JM; Ehrhardt MJ; Campbell MT; Noelle RJ; Blazar BR
Blood; 2002 Nov; 100(9):3400-7. PubMed ID: 12384443
[TBL] [Abstract][Full Text] [Related]
50. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.
Betts BC; Pidala J; Kim J; Mishra A; Nishihori T; Perez L; Ochoa-Bayona JL; Khimani F; Walton K; Bookout R; Nieder M; Khaira DK; Davila M; Alsina M; Field T; Ayala E; Locke FL; Riches M; Kharfan-Dabaja M; Fernandez H; Anasetti C
Haematologica; 2017 May; 102(5):948-957. PubMed ID: 28104702
[TBL] [Abstract][Full Text] [Related]
51. Graft-versus-host disease after bone marrow transplantation for thalassemia: an analysis of incidence and risk factors.
Gaziev D; Polchi P; Galimberti M; Angelucci E; Giardini C; Baronciani D; Erer B; Lucarelli G
Transplantation; 1997 Mar; 63(6):854-60. PubMed ID: 9089226
[TBL] [Abstract][Full Text] [Related]
52. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes.
Chen YB; Wang T; Hemmer MT; Brady C; Couriel DR; Alousi A; Pidala J; Urbano-Ispizua A; Choi SW; Nishihori T; Teshima T; Inamoto Y; Wirk B; Marks DI; Abdel-Azim H; Lehmann L; Yu L; Bitan M; Cairo MS; Qayed M; Salit R; Gale RP; Martino R; Jaglowski S; Bajel A; Savani B; Frangoul H; Lewis ID; Storek J; Askar M; Kharfan-Dabaja MA; Aljurf M; Ringden O; Reshef R; Olsson RF; Hashmi S; Seo S; Spitzer TR; MacMillan ML; Lazaryan A; Spellman SR; Arora M; Cutler CS
Bone Marrow Transplant; 2017 Mar; 52(3):400-408. PubMed ID: 27941764
[TBL] [Abstract][Full Text] [Related]
53. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment.
Arai S; Margolis J; Zahurak M; Anders V; Vogelsang GB
Biol Blood Marrow Transplant; 2002; 8(3):155-60. PubMed ID: 11939605
[TBL] [Abstract][Full Text] [Related]
54. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease.
MacMillan ML; Weisdorf DJ; Davies SM; DeFor TE; Burns LJ; Ramsay NK; Wagner JE; Blazar BR
Biol Blood Marrow Transplant; 2002; 8(1):40-6. PubMed ID: 11858189
[TBL] [Abstract][Full Text] [Related]
55. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids.
Doney KC; Weiden PL; Storb R; Thomas ED
Am J Hematol; 1981; 11(1):1-8. PubMed ID: 7023233
[TBL] [Abstract][Full Text] [Related]
56. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease.
Cragg L; Blazar BR; Defor T; Kolatker N; Miller W; Kersey J; Ramsay M; McGlave P; Filipovich A; Weisdorf D
Biol Blood Marrow Transplant; 2000; 6(4A):441-7. PubMed ID: 10975513
[TBL] [Abstract][Full Text] [Related]
57. Impact of Donor Statin Treatment on Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
Rashid N; Gooley T; Furlong T; Lee SJ; Martin PJ; Storb R; Mielcarek M
Transplant Cell Ther; 2023 Nov; 29(11):701.e1-701.e8. PubMed ID: 37657769
[TBL] [Abstract][Full Text] [Related]
58. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study.
Nash RA; Etzioni R; Storb R; Furlong T; Gooley T; Anasetti C; Appelbaum FR; Doney K; Martin P; Slattery J
Blood; 1995 Jun; 85(12):3746-53. PubMed ID: 7540071
[TBL] [Abstract][Full Text] [Related]
59. Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity.
Chohan R; Vij R; Adkins D; Blum W; Brown R; Tomasson M; Devine S; Graubert T; Goodnough LT; DiPersio JF; Khoury H
Br J Haematol; 2003 Oct; 123(1):110-3. PubMed ID: 14510951
[TBL] [Abstract][Full Text] [Related]
60. [Clinical analysis of sirolimus as an alternative GVHD prophylaxis for patients with kidney injury undergoing allo-HSCT].
Sun W; Ma R; He Y; Bai L; Chen YY; Chen Y; Zhang YY; Wang JZ; Chen H; Zhang XH; Xu LP; Wang Y; Huang XJ; Sun YQ
Zhonghua Nei Ke Za Zhi; 2023 Dec; 62(12):1444-1450. PubMed ID: 38044071
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
